TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31977628
Drug: 0.05 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 μg/kg/min norepinephrine infusion
Study: 31977628
Drug: 0.06 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 μg/kg/min norepinephrine infusion
Study: 31977628
Drug: 0.07 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 μg/kg/min norepinephrine infusion
Study: 31977628
Drug: 0 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 μg/kg/min norepinephrine infusion (control)
Study: 30477937
Drug: Regorafenib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (160 mg/day for 21 of 28 days)
Study: 28342829
Drug: Intensive peer
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive peer mentoring (weekly meetings during inpatient stay and weekly contact for 90 days postdischarge)
Study: 17387223
Drug: Yttrium-90 ibritumomab
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yttrium-90 ibritumomab tiuxetan (single dose)
Study: 12808776
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oxytocin (starting at 10 mIU/minute)
Study: 12808776
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oxytocin (starting at 4 mIU/minute)
Study: 12808776
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (high and low dose)
Study: 17012095
Drug: Psycho-education (PE)
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-education (PE) program (four 60-minute weekly manual driven sessions)
Study: 14668771
Drug: SPECT imaging
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECT imaging after sublingual administration of 10 mg isosorbide dinitrate
Study: 14668771
Drug: SPECT imaging
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECT imaging after nitrate administration
Study: 1279279
Drug: Isoprenaline (ISO)
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline (ISO) 1 microgram/min via intravenous infusion
Study: 1279279
Drug: Mepindolol TSD
Normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepindolol TSD patches
Study: 1279279
Drug: Placebo TSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo TSD patches
Study: 3905070
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefoxitin i.v. in the preoperative period
Study: 3905070
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefoxitin i.v. in the preoperative period + T tube suction drainage
Study: 30517731
Drug: Mediterranean-Style Eating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean-Style Eating Pattern with 500 g/wk of lean unprocessed red meat (Med-Red Pattern)
Study: 30517731
Drug: Mediterranean-Style Eating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean-Style Eating Pattern with 200 g/wk of lean unprocessed red meat (Med-Control Pattern)
Study: 26947568
Drug: Outpatient protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient protocol for weaning from tube to oral feeding (6-month program)
Study: 24882900
Drug: Eszopiclone (ESZ)
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eszopiclone (ESZ) 3 mg plus naproxen 500 mg BID
Study: 24882900
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus naproxen 500 mg BID
Study: 18319360
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg immediate release 3 times daily for 7 days
Study: 18319360
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg extended release once daily for 7 days
Study: 18319360
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg propiverine intravenously
Study: 18319360
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg immediate release administered at night
Study: 15703362
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet containing lamivudine, stavudine, and nevirapine (treatment A)
Study: 15703362
Drug: Separate marketed
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate marketed tablets administered simultaneously (treatment B)
Study: 15703362
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet (treatment A)
Study: 15703362
Drug: Separate marketed
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate marketed tablets (treatment B)
Study: 11168457
Drug: Protectamin (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protectamin (45 g daily for 2 weeks)
Study: 11990003
Drug: Protectamin (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protectamin (45 g daily for 6 months)
Study: 11168457
Drug: Immunocal (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunocal (45 g daily for 2 weeks)
Study: 10418924
Drug: 1 microg
Normalized name: Alpha 1 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg dose of PncT
Study: 10418924
Drug: 3 microg
Normalized name: Calcitriol 3 microgram/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 microg dose of PncT
Study: 10418924
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg dose of PncT
Study: 10418924
Drug: Booster response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Booster response to three vaccine serotypes in the group primed with the lowest dose of conjugate vaccine (1 microg)
Study: 2147884
Drug: L-dropropizine
Normalized name: dropropizine
DrugBank: Dropropizine (DB13785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dropropizine
Study: 10442379
Drug: Endocrine-only therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine-only therapy
Study: 18033754
Drug: Torcetrapib added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Torcetrapib added to atorvastatin (4 weeks)
Study: 10577754
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine and naloxone
Study: 6870623
Drug: Aminocaproic acid
Normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminocaproic acid (100 mg/kg every four hours for five days, max 30 g daily)
Study: 27825616
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg orally daily
Study: 26397228
Drug: Sorafenib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib treatment with low LDH serum levels
Study: 26397228
Drug: Sorafenib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib treatment with high LDH serum levels
Study: 26397228
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without sorafenib
Study: 28611340
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) infusion for 72 hours
Study: 19524577
Drug: Placebo (dextrose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dextrose) infusion for 72 hours
Study: 15213040
Drug: Dietary inorganic
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary inorganic sulfur intake (0.17-0.27 g S/d)
Study: 15213040
Drug: Average protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average protein intake (72 g/d)
Study: 15213040
Drug: Typical UK
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical UK intakes of inorganic sulfur (0.25 g/d)
Study: 10971248
Drug: Heparin-coated group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated group (n = 15; Quadrox Bioline oxygenator/reservoir and Carmeda BioMedicus BP-80 centrifugal pump)
Study: 10971248
Drug: Non-heparin-coated group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heparin-coated group (n = 12; uncoated oxygenator, centrifugal pump, tubing, and filter set)
Study: 10971248
Drug: Heparin-coated group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated group (n = 15)
Study: 10971248
Drug: Non-heparin-coated group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heparin-coated group (n = 12)
Study: 1520018
Drug: KabiVial 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: KabiVial 16 IU/ml combined with an Auto Injector
Study: 1520018
Drug: KabiPen 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: KabiPen 16 IU/ml
Study: 15870187
Drug: Ocinaplon (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocinaplon (total daily dose of 180-240 mg)
Study: 12676074
Drug: Ben 10
Normalized name: butamben 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ben 10 mg/d, po
Study: 12676074
Drug: Val 80
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Val 80 mg/d, po
Study: 12676074
Drug: Val 80
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Val 80 mg/d + Ben 10 mg/d, po
Study: 1829372
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg carbidopa every 8 h during ANP infusion
Study: 6421344
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug regimen (sodium fluoride, vitamin D, calcium gluconate, fluoxymesterone)
Study: 27253829
Drug: MDMA administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDMA administration in CYP2D6 poor metabolizers
Study: 22072272
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment 3×/wk during radiotherapy
Study: 20466163
Drug: Premix insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premix insulin (biphasic insulin aspart 30 [NovoMix 30])
Study: 20466163
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin (insulin detemir [Levemir])
Study: 20466163
Drug: Meal-time insulin
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal-time insulin (insulin aspart [NovoRapid])
Study: 20466163
Drug: All insulin
Normalized name: Small Insulin Syringe 1cc 31g
Approvals — FDA: no, EMA: no, PMDA: no
Description: All insulin analogs
Study: 17676985
Drug: Chemoprophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoprophylaxis with Deltaprim (3.125 mg of pyrimethamine plus 25 mg of dapsone)
Study: 11329231
Drug: Troglitazone, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone, 400 mg/d
Study: 9291302
Drug: Inactivated varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated varicella vaccine (single dose at 1 month after transplantation)
Study: 9291302
Drug: Inactivated varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated varicella vaccine (three doses at 1, 2, and 3 months after transplantation)
Study: 9291302
Drug: Inactivated varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated varicella vaccine (three doses)
Study: 8409112
Drug: ONO-1078, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-1078, 150 mg capsule, administered every 12 hours for 1 week
Study: 8409112
Drug: Placebo, inactive,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, inactive, administered every 12 hours for 1 week
Study: 3516203
Drug: Ibuprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1200 mg daily)
Study: 29444611
Drug: Goreisan (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goreisan (7.5 g daily for 12 weeks)
Study: 27554053
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (applied 10 hours previously)
Study: 22549090
Drug: GTU(®)-Multi-HIVB vaccine
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTU(®)-Multi-HIVB vaccine (1mg/dose IM at 0, 4, 12 weeks, boosted at 76 and 80 weeks with 2mg/dose)
Study: 17276548
Drug: Oral indomethacin/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral indomethacin/acetaminophen combination therapy
Study: 17276548
Drug: Oral prednisolone/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone/acetaminophen combination therapy
Study: 16198660
Drug: BAY 59‐‐7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59‐‐7939 (1.25‐‐80 mg)
Study: 16198660
Drug: BAY 59‐‐7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59‐‐7939 (5‐mg tablet and oral solution)
Study: 12189361
Drug: Valganciclovir (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (900 mg oral administration)
Study: 8849180
Drug: Doxycycline plus
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline plus ketoprofen (doxycycline 100 mg twice daily for 10 days plus ketoprofen 200 mg daily for 10 days)
Study: 8849180
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice daily for 10 days)
Study: 21733319
Drug: Pistachio nuts
Normalized name: Pistachio nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistachio nuts (0, 42, and 84 g/d)
Study: 21148614
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg) once daily
Study: 15780846
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Delta‐9‐THC
Study: 15780846
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg Delta‐9‐THC
Study: 2255839
Drug: Ivermectin 200
Normalized name: ivermectin 200 ug / praziquantel 1.5 mg ORAL PASTE [Equimax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 200 mcg/kg
Study: 1996738
Drug: Ivermectin 400
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 400 mcg/kg (200 mcg/kg per day for 2 days)
Study: 1996738
Drug: Ivermectin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (1 mg oral dose)
Study: 6340972
Drug: Fentiazac 400
Normalized name: fentiazac
DrugBank: Fentiazac (DB13217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentiazac 400 mg daily
Study: 6340972
Drug: Sulindac 200
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 200 mg daily
Study: 25245218
Drug: CCRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT with 20 mg/m2 cisplatin for 5 days
Study: 21848925
Drug: Internet-based blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based blood glucose monitoring system (submitted weekly for 6 months)
Study: 17440420
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion threshold (10 g/dL hemoglobin)
Study: 17440420
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion threshold (7 g/dL hemoglobin)
Study: 12384647
Drug: L-arginine (L-A)
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (L-A) infusion at a rate of 1.5 g/min for 20 min
Study: 9563145
Drug: Dibenyline 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dibenyline 10 mg b.i.d. (n = 71)
Study: 9563145
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg q.d. (n = 54)
Study: 9563145
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dibenyline and finasteride (n = 65)
Study: 27630504
Drug: Perio Q(TM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perio Q(TM) gel + SRP
Study: 27630504
Drug: tea tree
Normalized name: tea tree
DrugBank: Melaleuca alternifolia leaf (DB14372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tea tree oil gel + SRP
Study: 27630504
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gel + SRP
Study: 23249098
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment for 32 weeks
Study: 23249098
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment for 20 weeks
Study: 21041813
Drug: 9 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g/d oligofructose-enriched inulin in a calcium-fortified cereal
Study: 9730069
Drug: Oral mucosal
Normalized name: Finafta Multi Oral Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mucosal adhesive film containing dibucaine (DC) at a dose of 0.113 mg/cm2
Study: 9730069
Drug: Oral mucosal
Normalized name: Finafta Multi Oral Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mucosal adhesive film containing dibucaine (DC) at a dose of 0.225 mg/cm2
Study: 12859302
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg i.v.
Study: 8137516
Drug: GH-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH-releasing hormone 1 microgram/kg body weight
Study: 8137516
Drug: GH-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH-releasing hormone without dexamethasone pretreatment
Study: 2605801
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of perindopril
Study: 2605801
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of perindopril
Study: 2605801
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of perindopril
Study: 1159330
Drug: Gentamicin sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin sulfate (1.5 mg/kg) intravenous injection
Study: 1159330
Drug: Gentamicin sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin sulfate (1.5 mg/kg) intramuscular injection
Study: 28678332
Drug: Strength group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength group (oral hypoglycemic medications, subcutaneous insulin infusion, or continuous infusion by micropump)
Study: 28678332
Drug: Mitigation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitigation group (personalized treatment programs)
Study: 11834234
Drug: Leios (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leios (0.02 mg ethinyl estradiol and 0.1 mg levonorgestrel)
Study: 11834234
Drug: Stediril 30
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stediril 30 (0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel)
Study: 22840866
Drug: Tamsulosin 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.8 mg
Study: 3278498
Drug: Indomethacin (25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25‐50 mg bolus plus infusion, 5‐7.5 mg h‐1) in lactated Ringer solution
Study: 30573769
Drug: Interactive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive group format treatment (6 sessions, 2 hours each, one session per week)
Study: 30573769
Drug: Interactive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive group format treatment
Study: 31347489
Drug: Test canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test canagliflozin formulation (100 mg)
Study: 31347489
Drug: Reference canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference canagliflozin formulation (100 mg)
Study: 10599729
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment group A, 4 IU/m2 x day
Study: 10599729
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment group B, first year 4 and thereafter 6 IU/m2 x day
Study: 10599729
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment group C, first year 4, second year 6, and thereafter 8 IU/m2 x day
Study: 10599729
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment groups A, B, C
Study: 10599729
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment group A
Study: 7657044
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment (control group)
Study: 1932297
Drug: Ceftazidime with
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime with amikacin (1.5 g/day)
Study: 6211997
Drug: Althesin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Althesin infusion
Study: 12849808
Drug: Unopposed hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unopposed hormone therapy (CEE)
Study: 12849808
Drug: Opposed hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opposed hormone therapy (CEE and medroxyprogesterone acetate)